Stephen Marley Launches Plant-Based CBD Personal Care Line

Dec.14.2022
Stephen Marley Launches Plant-Based CBD Personal Care Line
Stephen Marley releases plant-based Kx Family Care, featuring CBD-infused Hair and Beard Oil, Pain Relief Balm, and more.

On Monday, Grammy-winning artist Stephen Marley launched a product line called Kx Family Care, which is a plant-based CBD personal care collection that utilizes the benefits of cannabis and other herbs traditionally used in Jamaica.


The debut series features limited holiday packages containing two products: a versatile hair and beard oil, and a pain relief balm both infused with full spectrum CBD oil, known for its anti-inflammatory, antibacterial, and antioxidant properties.


These two products also contain sunflower oil, vitamin E, and linoleic acid, which have antioxidants that help protect the skin from free radical damage and maintain its natural barrier. They also contain black seed oil, sapodilla fruit extracts, and star apple, which are widely used in Jamaican culture for their regenerative properties.


For example, Jamaican black castor oil comes from the seeds of the Nigella sativa plant, which is rich in antioxidants and offers various health benefits.


Kx Family Care is a natural progression for me, due to my passion for the cannabis plant and its various uses," said founder Stephen Marley. "This brand is authentic in every way, from the natural infusion of Jamaican plants in our products, to the eco-friendly wood and glass packaging we use. Our goal is centered on family, natural health, sustainability, and respect for the many uses of the cannabis plant.


Kx Family Care is the multi-generational personal-care product branch of Kaya Lifestyle, owned and operated by Marley. Kaya Lifestyle also hosts Kaya Fest, a music and education cannabis advocacy festival.


Marley joined the CEO and co-founder Shelly O'Neill to spend three years researching and developing a plant-based, multipurpose product designed specifically for busy families. Marley believes that marijuana is just like any other useful herb. "Marijuana is an herb, like mint or sage, that can cure many diseases and provide spiritual enlightenment," Marley told the cultural magazine in 2018.


The idea for Kx Family Care arose while O'Neill and Marley were working together at Kaya Fest, a world music festival organized by Marley to promote education surrounding the various uses of the cannabis plant. The term "Kaya" is a Jamaican slang word for herb, derived from the Caribbean English word "kayakiit," meaning a type of herb.


Experience Marley's cannabis products firsthand: Kx Family Care's pop-up store will be opening on specific dates during Stephen Marley's upcoming Old Soul Tour - Unplugged 2023.


We are pleased to introduce the first all-natural, cannabis-based personal care brand that is safe and effective for the entire family," said founder Stephen Marley. "We look forward to giving our customers a firsthand experience of the Kx Family Care pop-up store at the specific date of The Old Soul Tour - Unplugged in 2023.


The company stated that the US Food and Drug Administration (FDA) does not require basic safety testing on ingredients in personal care products. These products often contain toxic ingredients that can harm the skin and hair.


The company also maintains its commitment to the environment in its packaging.


Kx Family Care aims to utilize eco-friendly materials including hemp plastic to showcase the various uses of the cannabis plant and reduce plastic waste, according to its website. Inspired by Jamaica's nickname as the "land of wood and water," the company captures the essence by using biodegradable wood and glass in its packaging. Kx also spreads love by supporting different charitable organizations every quarter with a portion of its sales revenue.


Several siblings and family members of Marley have ventured into the CBD or cannabis business, including Ziggy and Damian.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia’s withdrawal of its appeal in a landmark liquid-nicotine case has left a High Court ruling that struck down the 2023 nicotine exemption in force, bringing liquid and gel nicotine used in vaping products back under the Poisons Act 1952. At the same time, the Control of Smoking Products for Public Health Act 2024 continues to provide a regulatory framework for vaping products, creating uncertainty over retail sales, taxation and existing inventory. MPs are calling for nicotine vape sales and excise collection to stop, including refunds of more than RM354 million collected since 2023, while industry and consumer groups are asking the government to clarify the current legal position.
Sep.04
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada's federal government is considering changes to current restrictions on where nicotine pouches can be sold, potentially allowing authorized products to return to convenience stores and other general retail channels, although no decision has been made. Since 2024, emerging nicotine replacement therapy products such as nicotine pouches have been largely restricted to behind-the-counter pharmacy sales. Health Canada, meanwhile, continues to recall unauthorized and higher-strength nicotine pouches, indicating that the current discussion concerns retail access for authorized products rather than a broad relaxation of nicotine pouch regulation.
Sep.14